Briacell Therapeutics (NASDAQ: BCTX) — Perfil da empresa, notícias e dados financeiros
BriaCell Therapeutics develops targeted immunotherapies for cancer, focusing on innovative vaccine technology.
Briacell Therapeutics
BriaCell Therapeutics (NASDAQ:BCTX) focuses on the development of targeted and effective immunotherapies for cancer. The cornerstone of their operations is their novel cancer vaccine technology, which aims to harness the patient's immune system to combat cancer cells specifically and effectively. BriaCell's leading project, a clinical stage breast cancer treatment, showcases their commitment to advancing cancer therapy through innovative research and development. Their objective is to transform cancer treatment by developing therapies that are not only potent but also less toxic and more tolerable for patients, aiming to improve quality of life alongside extending survival rates.
Resumo
Operações
Produtos e/ou serviços de Briacell Therapeutics
- Bria-IMT™, a novel immunotherapy for advanced breast cancer aiming to stimulate the immune system to attack tumor cells.
- Bria-OTS™, an off-the-shelf personalized immunotherapy designed for a wide patient population with minimum manufacturing time.
- BriaDX™, a diagnostic test to predict patient compatibility with their immunotherapies, enhancing treatment precision and effectiveness.
- BriaCell's clinical trial collaboration with Incyte Corporation, exploring novel combination treatments to further improve patient outcomes in advanced breast cancer.
- Development of next-generation cancer vaccines focusing on lung, prostate, and melanoma, intended to provide targeted, effective treatment options.
- Research into immune system modulators to enhance the efficacy of their cancer immunotherapies, aiming to improve survival rates and quality of life for patients.
equipe executiva do Briacell Therapeutics
- William V. WilliamsCEO, President & Director
- Gadi LevinCFO & Corporate Secretary
- Miguel A. Lopez-LagoChief Scientific Officer
- Giuseppe Del PrioreChief Medical Officer
- Charles Louis WisemanFounder, Principal Research Advisor & Member of Scientific Advisory Board
Últimas notícias sobre a Briacell Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Briacell Therapeutics .
- Cap. de mercado
- 30,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | — | -34,9 mi | |
| — | -37,7 mi | -36,5 mi | |
| 0 | -33,3 mi | -4,8 mi | |
| 0 | -31,1 mi | -27,1 mi |